Blavatnik Center for Drug Discovery

Blavatnik Center for Drug Discovery
Name	Blavatnik Center for Drug Discovery
Established	2012
Location	Tel Aviv University, Tel Aviv-Yafo, Israel
Type	Research center
Focus	Pharmaceutical chemistry, Chemical biology, Translational medicine
Director	Dennis Brown

Blavatnik Center for Drug Discovery is an academic drug discovery center based at Tel Aviv University supporting small-molecule and biologics development for academic translational projects. The center integrates medicinal chemistry, high-throughput screening, structural biology and pharmacology to advance candidates toward preclinical development and industry partnerships. It operates at the intersection of academic research, biotechnology startups and philanthropic funding, engaging with global partners in Israel, the United States, and Europe.

Overview

The center provides infrastructure for lead identification, lead optimization, and early safety assessment, combining expertise from Medicinal chemistry laboratories, Structural biology facilities, and High-throughput screening platforms. It houses instrumentation often found in facilities affiliated with Weizmann Institute of Science, Cold Spring Harbor Laboratory, and Broad Institute, including automated liquid handlers, mass spectrometers, and X-ray crystallography suites. The center serves investigators from departments such as Biochemistry, Molecular Biology, Pharmacology, and interacts with translational organizations like Yissum Research Development Company, Kauffman Foundation, and venture groups similar to Sequoia Capital and Atlas Venture.

History and Funding

Founded in 2012 with support from private philanthropy, the center was financed through gifts related to major donors linked to the Blavatnik Family Foundation and institutional fundraising at Tel Aviv University. Its establishment followed trends in university-affiliated translational centers exemplified by institutions such as Harvard University's translational initiatives and University of Cambridge spinout ecosystems. Funding streams include philanthropic endowments, competitive grants from agencies like the European Research Council and Israel Science Foundation, and collaborative sponsored research agreements with biotechnology firms modeled on partnerships seen with Pfizer, Novartis, and GlaxoSmithKline.

Research Programs and Facilities

Research programs span target identification, assay development, cheminformatics, and in vivo pharmacology, drawing on methodologies practiced at Massachusetts Institute of Technology, Stanford University, and Imperial College London. Facilities include medicinal chemistry laboratories compatible with standards of the American Chemical Society, a compound management library analogous to collections at the European Molecular Biology Laboratory, and access to cryo-electron microscopy workflows similar to those at Max Planck Institute for Biophysical Chemistry. The center supports structure-based drug design using resources such as the Protein Data Bank, computational chemistry tools employed at Lawrence Livermore National Laboratory, and ADMET profiling workflows consistent with guidance from agencies like the U.S. Food and Drug Administration.

Collaborations and Partnerships

The center collaborates with academic groups and industry partners, following models of partnership between Johns Hopkins University and biotech firms, or between University of Oxford and pharmaceutical consortia. It engages with startup incubators and technology transfer offices such as Yozma-style initiatives and coordinates joint projects with clinical departments at Sheba Medical Center and community hospitals. International links include cooperative programs with institutions like the University of California, San Francisco, Columbia University, and Technion – Israel Institute of Technology, and engagement with multinational companies similar to Roche and Bayer for licensing and co-development.

Notable Discoveries and Impact

Projects advanced at the center have produced lead series and preclinical candidates across therapeutic areas including oncology, infectious disease, and neurodegeneration, echoing translational outcomes seen at centers like Scripps Research and Dana–Farber Cancer Institute. Outputs include peer-reviewed publications indexed in journals such as Nature, Science, Cell, and specialty periodicals like Journal of Medicinal Chemistry and ACS Chemical Neuroscience. The center’s work has contributed to patent filings and spinout companies comparable to startups originating from Massachusetts General Hospital and The Rockefeller University, and has influenced regional biotech growth in the Tel Aviv District and broader Israeli startup ecosystem.

Administration and Personnel

Administrative oversight aligns with university governance at Tel Aviv University and involves interface with offices comparable to Technology Transfer Office (TTO) structures at University of Pennsylvania. Scientific leadership comprises principal investigators drawn from departments such as Sackler Faculty of Medicine and associated faculties, with teams that include medicinal chemists, structural biologists, pharmacologists, and project managers. Training programs and fellowships mirror career-development schemes offered by organizations like the European Molecular Biology Organization and Howard Hughes Medical Institute, supporting postdoctoral researchers and graduate students who transition into academic, clinical, or industry careers.

Category:Research institutes in Israel